Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing

Table 3 The RAS mutation status is maintained throughout disease course

Case ID#	RAS Mut.	PT	syn M[HEP] 1	syn M[PUL] 1	syn M[PUL] 2	met M[HEP] 1	met M[PUL] 1	met M[PUL] 2
1	KRAS G12D	55.59	97.28				16.77
2	KRAS G12V	53.59	89.98	47.32	32.82
3	KRAS G12V	21.92				45.26	0 and 21.22	34
4	WT	0	0			0	0
5	KRAS G12A	24.18	9.7^a	17.72	36.04
6	KRAS G12V	22.85				0	26.73
7	WT	0	0			0, 0
8	KRAS G13D	34.16	50.44	31.43			12.85
9	WT	0	0				0	0
10	WT	0				0	0
11	WT	0	0				0
12	KRAS G12A	99.74	56.72				34.15	19.63
13	KRAS G12D, G12V	19.83 (G12D)	16.44 (G12V)	5.62^a and 25.72 (G12V)
14	NRAS Q61R	44.31	66.91 and 44.74	46.17

The table summarizes the RAS status and mutated allele frequency (%) throughout the disease course of 9/14 mutated CRC cases. If two metastatic lesions were resected at the same time, the RAS status is given for both
^a= sequence variant detected at below 10 % allele frequency

ISSN: 1476-4598